Explore the Agenda
Pre-Conference Day
Tuesday, June 23, 2026
Day One
Wednesday, June 24, 2026
Day Two
Thursday, June 25, 2026
7:30 am Check-In & Light Refreshments
Discovery, Design & Engineering
Workshop A
8:30 am Harnessing Innate Immune Cell Biology to Address the Rise of NK, Macrophage & Multi-Lineage Engagers for Enhanced Anti-Tumor Responses
Join this workshop to explore how emerging innate immune cell engagers are reshaping the next generation of T-cell engager therapeutics and overcoming resistance, improving safety, and expanding potential in solid tumors.
- Identifying high-value innate immune targets, including NK activating and inhibitory receptors, and macrophage checkpoint pathways to overcome tumor immune suppression
- Evaluating the advantages and limitations of NK, macrophage, and multi-lineage engagers compared to traditional T-cell engagers
- Exploring engineering considerations for multi-functional molecules, including avidity, geometry, immune synapse formation, and balancing potency with safety
- Discussing appropriate preclinical and translational models to evaluate innate immune engagement, including humanized systems and tumor microenvironment platforms
- Defining safety considerations and the minimum preclinical data package required to justify advancing NK, macrophage, or multi-lineage engagers into clinical development
Preclinical & Translational Development
Workshop D
8:30 am Navigating Safety & Efficacy Challenges by Engineering Approaches to Accelerate Development of Clinically-Relevant T-Cell Engagers
T‑cell engagers have delivered clear clinical benefit in hematologic malignancies, yet broader application, particularly in solid tumours and autoimmune diseases, has been limited by safety and efficacy barriers. This session will explore how next‑generation engineering strategies are helping to overcome these challenges.
- Addressing tumour heterogeneity and antigen escape through multi‑specific designs, affinity tuning, and improved target selection
- Overcoming the immunosuppressive tumour microenvironment, which limits T‑cell activation and persistence in solid tumours
- Mitigating cytokine release syndrome (CRS) by refining CD3 binding, format, valency, and dosing strategies
- Reducing on‑target, off‑tumour toxicity via conditional activation, masking approaches, and improved tumour selectivity
- Showcasing recent clinical success stories in solid tumours enabled by rational TCE engineering
10:30 am Morning Break & Networking
Workshop B
11:00 am Engineering Molecular Geometry to Optimize Multispecific T-Cell Engagers for Better Developability
Join this workshop to master the structural complexity of next generation multispecifics, where the focus shifts from simple binding to the precise spatial coordination of the immunological synapse.
- Designing trispecifics that require two tumor antigens to trigger engagement, widening the therapeutic window
- Engineering trispecifics that require two different tumor antigens to trigger CD3 engagement, significantly widening the therapeutic index for antigens
- Overcoming engineering hurdles to ensure the two components of the TCE only meet on the tumor cell surface
- Technical deep-dive into target identification using TCR-target discovery engines to reduce minimal off-target reactivity
- Identifying the optimal inter-membrane distance and how the choice of epitopes on the tumor antigen dictates efficacy
Workshop E
11:00 am Revolutionizing Bench to Bedside Transitions by Optimizing a Comprehensive Translational Package to Accelerate Clinical Entry
Join this workshop to bridge the critical gap between preclinical promise and clinical reality, where the focus shifts from molecular potency to the power of a translational data package
- Discussing ideal assays for bankable safety data beyond TCRs, such as cytokine release assays and tissue models
- Evaluating the translational impact of Fc-silencing or Fcengineering on systemic inflammation and half-life in a nonanimal context
- Discussing the current gap in translational models for ICANS/ neurotoxicity and whether specialized neuro models are ready for IND inclusion
- Deep diving into how TCE developers are harnessing the modified MABEL approach to avoid ‘sub-therapeutic’ dose escalation and save cohorts
- Discussing how unexpected clinical outcomes should trigger new in vitro or ex vivo studies
1:00 pm Lunch & Networking
Workshop C
2:00 pm Transforming Precision Targeting by Leveraging AI-Driven Antigen Selection to Enable Highly Accurate TCE Design
Join this workshop to move beyond the “AI buzzword” and confront the biological hurdles of antigen heterogeneity. As we pivot toward more complex engineering, this session addresses the critical uncertainty of target density: determining whether 20% or 80% cellular expression is the threshold for clinical success.
- Using machine learning to synthesize datasets to profile antigen prevalence across primary vs. metastatic tissues
- Identifying which novel targets are tumor-specific versus those with risky low-level expression in healthy tissues
- Deep-diving into the antigen expression level needed to trigger the action of a T-cell engager
- Developing AI algorithms that move beyond simple “positive/ negative” IHC scores to more predictive “probability of response” scores based on complex expression patterns
- Discussing how clinical trial failures can be fed back into AI models to refine the next generation of discovery
Workshop F
2:00 pm Synchronizing Global Regulatory Strategies through Modelling & Translational Approaches for Next-Generation TCEs
Join this workshop to explore how mechanistic modelling, in vitro systems, and translational data can be used to address non-clinical gaps and support a shift from animal-heavy approaches toward predictive, weight-of-evidence frameworks.
- Identifying scientific inconsistencies across current non-clinical approaches, with a focus on the role and limitations of non-human primate data
- Applying PK/PD and systems-level modelling to support weight-of-evidence frameworks, clarify risk, and inform non-clinical decision-making
- Leveraging existing clinical and marketed product data, supported by comparative modelling, to strengthen confidence in new molecules
- Aligning modelling and translational strategies with differing global regulatory expectations to enable more consistent and efficient development pathways across regions
- Exploring how sponsors can proactively engage regulators with modelling-supported non-clinical packages to align on expectations early and avoid late-stage study requests